Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1295000.RAAwLOpC2bwvVbUbxG_kHkbZ3aLyCR8Y-REaPTVDP8GrA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1295000.RAAwLOpC2bwvVbUbxG_kHkbZ3aLyCR8Y-REaPTVDP8GrA130_assertion type Assertion NP1295000.RAAwLOpC2bwvVbUbxG_kHkbZ3aLyCR8Y-REaPTVDP8GrA130_head.
- NP1295000.RAAwLOpC2bwvVbUbxG_kHkbZ3aLyCR8Y-REaPTVDP8GrA130_assertion description "[However, the results of phase II trials of EGFR inhibitors-as well as other targeted agents--in salivary gland tumors have been disappointing: there has been some disease stabilization but no objective responses.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1295000.RAAwLOpC2bwvVbUbxG_kHkbZ3aLyCR8Y-REaPTVDP8GrA130_provenance.
- NP1295000.RAAwLOpC2bwvVbUbxG_kHkbZ3aLyCR8Y-REaPTVDP8GrA130_assertion evidence source_evidence_literature NP1295000.RAAwLOpC2bwvVbUbxG_kHkbZ3aLyCR8Y-REaPTVDP8GrA130_provenance.
- NP1295000.RAAwLOpC2bwvVbUbxG_kHkbZ3aLyCR8Y-REaPTVDP8GrA130_assertion SIO_000772 26470903 NP1295000.RAAwLOpC2bwvVbUbxG_kHkbZ3aLyCR8Y-REaPTVDP8GrA130_provenance.
- NP1295000.RAAwLOpC2bwvVbUbxG_kHkbZ3aLyCR8Y-REaPTVDP8GrA130_assertion wasDerivedFrom befree-2016 NP1295000.RAAwLOpC2bwvVbUbxG_kHkbZ3aLyCR8Y-REaPTVDP8GrA130_provenance.
- NP1295000.RAAwLOpC2bwvVbUbxG_kHkbZ3aLyCR8Y-REaPTVDP8GrA130_assertion wasGeneratedBy ECO_0000203 NP1295000.RAAwLOpC2bwvVbUbxG_kHkbZ3aLyCR8Y-REaPTVDP8GrA130_provenance.